Exome Sequencing Disclosures in Pediatric Cancer Care: Patterns of Communication among Oncologists, Genetic Counselors, and Parents

Exome sequencing (ES) and other clinical next-generation sequencing tests have the potential to impact childhood cancer care through discovery of somatic mutations or germline cancer susceptibility mutations, in addition to clinically significant incidental findings unrelated to the test indication.[1,2] While studies have examined the perspectives of pediatric oncologists, parents and patients regarding ES through interviews and surveys [3,4], understanding the communication of ES results is still limited.

Source: Patient Education and Counseling - November 12, 2018 Category: International Medicine & Public Health Authors: Sarah Scollon, Mary A. Majumder, Katie Bergstrom, Tao Wang, Amy L. McGuire, Jill O. Robinson, Amanda M. Gutierrez, Caroline H. Lee, Susan G. Hilsenbeck, Sharon E. Plon, D. Williams Parsons, Richard L. Street Source Type: research